tradingkey.logo
tradingkey.logo
Search

Novo Nordisk Says FDA Accepts Filing Application For oral semaglutide 25 mg

ReutersMay 2, 2025 7:06 PM
facebooktwitterlinkedin
View all comments0

- Novo Nordisk A/S NOVOb.CO:

  • FDA ACCEPTS FILING APPLICATION FOR ORAL SEMAGLUTIDE 25 MG, WHICH IF APPROVED, WOULD BE THE FIRST ORAL GLP-1 TREATMENT FOR OBESITY

  • NOVO NORDISK -FDA ACTION DATE TO DECIDE ON WEGOVY(®) ORAL FORMULATION NDA WILL BE IN Q4 2025

Further company coverage: [NOVOb.CO]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI